Form 4: Opaleye Management Inc. Reduces Stake in Protara Therapeutics

Opaleye Management Inc. reports the sale of Protara Therapeutics shares over two days, reducing its beneficial ownership.

Summary

• Opaleye Management Inc., a 10% owner of Protara Therapeutics, Inc., filed a Form 4 detailing changes in beneficial ownership.
• On May 9, 2024, Opaleye Management Inc. sold 30,600 shares of Protara Therapeutics common stock at a weighted average price of $3.0891 per share.
• On May 10, 2024, the firm sold an additional 151,700 shares at a weighted average price of $3.1142 per share.
• Following these transactions, Opaleye Management Inc. beneficially owns 2,380,294 shares of Protara Therapeutics common stock through Opaleye, L.P.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the reduction in ownership by a major shareholder, which could indicate a lack of confidence or a strategic shift.

Negatives

• Opaleye Management Inc. reduced its stake in Protara Therapeutics, which could be perceived negatively by investors.

Risks

• Continued selling pressure from Opaleye Management Inc. could further depress the stock price of Protara Therapeutics.

Industry Context

Sales of shares by significant shareholders are common and can be driven by various factors, including portfolio rebalancing or profit-taking. The impact on the stock price depends on the size of the sale relative to the trading volume and overall market sentiment.

Stakeholder Impact

• Shareholders may react to the news of Opaleye Management Inc.'s reduced stake, potentially leading to price volatility.
• The company may need to address investor concerns regarding the reasons for the sale.

Key Dates